Intravenous Thrombolysis and Risk Factors for Ischemic Stroke

Thrombolysis is one of the proven potential treatments for the management of acute ischemic stroke. Intravenous recombinant tissue-plasminogen activator (rt-PA) is the only medically approved biological thrombolysing agent for the treatment of acute ischemic stroke within 4.5h of stroke (2.2% sympto...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Nepal Medical Association 2014-01, Vol.52 (193), p.745-750
Main Authors: Shrestha, Shakti, Poudel, Ramesh Sharma, Thapa, Lekh Jung, Khatiwada, Dipendra
Format: Article
Language:English
Subjects:
Administration, Intravenous
Age Factors
Antihypertensive Agents - therapeutic use
Atrial Fibrillation - epidemiology
Comorbidity
Diabetes Mellitus - epidemiology
Early Medical Intervention
Fibrinolytic Agents - therapeutic use
Humans
Hyperlipidemias - epidemiology
Hypertension - drug therapy
Hypertension - epidemiology
Risk Factors
Sex Factors
Smoking - epidemiology
Stroke - drug therapy
Stroke - epidemiology
Thrombolytic Therapy - methods
Tissue Plasminogen Activator - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thrombolysis is one of the proven potential treatments for the management of acute ischemic stroke. Intravenous recombinant tissue-plasminogen activator (rt-PA) is the only medically approved biological thrombolysing agent for the treatment of acute ischemic stroke within 4.5h of stroke (2.2% symptomatic intracerebral haemorrhage, 12.7% mortality and 58.0% functional independence), but following the guideline and criteria provided by National Institute of Neurological Disorder and Stroke (NINDS) and SITS (Safe Implementation of Thrombolysis in Stroke) studies. Nepal needs to evidently introduce intravenous rt-PA in its clinical setting for treatment of acute ischemic stroke, which has been approved for more than a decade ago in developed countries. Several modifiable and non-modifiable risk factors can affect the outcomes of the treatment with intravenous rt-PA. Early modification of factors predicting the risk outcomes can be a beneficial tool to justify the thrombolytic treatment. This review aims to discuss the major studies on thrombolysis using rt-PA and main factors that can affect the outcomes of treatment in ischemic stroke.
ISSN:0028-2715
1815-672X
DOI:10.31729/jnma.2615